NCT05889299已完成1 期
A Phase 1b Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 2
- 主要终点
- To assess overall safety and tolerability of repeat-dose OMS906 5 mg/kg SC administration at 4-week intervals in patients with PNH.
研究概览
简要总结
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).
详细描述
This is a Phase 1b, proof of concept, open-label, uncontrolled study. The primary objective is to assess the safety and tolerability of OMS906 in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). The study evaluated 3 dosing regimens: (1) 5 mg/kg SC administered every 4 weeks (Q4W), (2) 5 mg/kg IV administered once followed by administration of additional doses of 5 mg/kg IV at the occurrence of protocol-defined subclinical breakthrough hemolysis, and (3) 8 mg/kg IV every 8 weeks (Q8W) on a fixed-dosing (FD) schedule
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Confirmed diagnosis of PNH by flow cytometry with PNH clone size of >10% RBCs and/or granulocytes.
- •Male or female adults 18 years and older.
- •Competent to provide consent and completed informed consent procedures.
- •Patients who are not receiving complement inhibitor treatment or, alternatively, patients currently treated with eculizumab or ravulizumab with an inadequate response to treatment defined as a Hgb <10.5 g/dL. Patients receiving eculizumab or ravulizumab must be on stable doses for at least 6 months.
- •Hemoglobin level <10.5 g/dL at screening and baseline.
- •Lactate dehydrogenase >1.5 upper limit of normal (ULN) for patients not receiving eculizumab or ravulizumab.
- •Female patients of child-bearing potential (CBP) must have a negative serum test at screening and highly sensitive urine pregnancy test prior to each dose of OMS
- •Females must use highly effective birth control to prevent pregnancy during the clinical trial and for 20 weeks (140 days) following their last dose of study drug.
- •Males must use highly effective birth control with a female partner to prevent pregnancy during the clinical trial and for 20 weeks (140 days) following their last dose of study drug.
- •Have received vaccination for Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae (if locally available). Patients who have not received these vaccinations at the time of screening may be vaccinated at any time prior to 2 weeks before the first study drug administration. Patients enrolled in the study at the time of Amendment 02 may receive S. pneumoniae and H. influenzae vaccinations, if not already vaccinated, at their next scheduled visit.
排除标准
- •Treatment with any complement pathway inhibitor except eculizumab or ravulizumab within the 6 months prior to screening.
- •For patients not receiving eculizumab or ravulizumab at the time of screening: receipt of eculizumab within 8 weeks prior to screening or receipt of ravulizumab within 24 weeks prior to screening.
- •History of major organ transplant or hematopoietic stem cell/bone marrow transplant.
- •Reticulocyte count <100,000 /µL, transfusion-free platelet count <30,000/µL or absolute neutrophil count <500 cells/µL at screening.
- •Anemia attributable to any other medical condition apart from PNH.
- •Elevation of liver function tests, defined as total bilirubin >2×ULN, direct bilirubin >1.5xULN, and elevated transaminases, alanine aminotransaminase (ALT) or aspartate transaminase (AST), >2×ULN unless due to PNH related hemolysis.
- •History of any severe hypersensitivity reactions to other monoclonal antibodies or excipients included in the OMS906 preparation.
- •Significant active bacterial, fungal, or viral infection within the 2 weeks of OMS906 drug initiation, including COVID-19 infection.
- •History of primary or secondary immunodeficiency or complement deficiency.
- •Have human immunodeficiency virus, hepatitis B or untreated hepatitis C infection.
- •History of splenectomy.
- •History or prior bacterial meningitis or N. meningitidis infection.
- •Patients on immunosuppressive agents such as but not limited to cyclosporine, mycophenolate mofetil (MMF), tacrolimus, cyclophosphamide, or methotrexate less than 8 weeks prior to first treatment with OMS906 unless on a stable regimen for at least 3 months prior to screening.
- •Patients who require recurrent short courses of systemic corticosteroids (i.e., >4 short courses per year of >2 weeks in duration per course).
- •Pregnant, planning to become pregnant, or nursing female patients.
- •Recent surgery requiring general anesthesia within the 2 weeks prior to screening or expected to have surgery requiring general anesthesia during the treatment periods.
- •History of any clinically significant medical, neurologic, or psychiatric disorder that in the opinion of the investigator would make the patient unsuitable for participation in the study.
- •Treatment with any investigational medicinal product or investigational device within the 30 days (or within 5x its half-life in days, whichever is the longer period) prior to screening or participation in another concurrent clinical trial involving a therapeutic intervention. Participation in observational studies and/or registry studies is permitted.
- •Unable or unwilling to comply with the requirements of the study.
结局指标
主要结局
To assess overall safety and tolerability of repeat-dose OMS906 5 mg/kg SC administration at 4-week intervals in patients with PNH.
时间窗: 48 weeks
Number of participants with treatment-emergent adverse events assessed by CTCAE v5.0 and changes in laboratory measures, ECGs and physical examination.
次要结局
- To assess preliminary efficacy by the effect on hemolysis and anemia measured by red blood cell (RBC) transfusion burden.(48 weeks)
- To assess preliminary efficacy by the effect on hemolysis and anemia measured by Lactate dehydrogenase (LDH).(48 weeks)
- To assess preliminary efficacy by the effect on hemolysis and anemia measured by hemoglobin (Hgb).(48 weeks)
- To assess preliminary efficacy measured by PK, PD, and ADA.(48 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to RavulizumabParoxysmal Nocturnal HemoglobinuriaNCT05972967Omeros Corporation12
招募中
2 期
Safety and Efficacy Study of OMS906 in Patients With C3G and ICGNC3 GlomerulopathyIdiopathic Immune Complex-Mediated GlomerulonephritisNCT06209736Omeros Corporation20
已完成
1 期
Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of PA1010 in HBV PatientsChronic HBV InfectionNCT05019040Zhejiang Palo Alto Pharmaceuticals, Inc.36
招募中
1 期
The Study of ICP-248 in Patients With Mature B-cell MalignanciesHematological MalignanciesNCT05728658Beijing InnoCare Pharma Tech Co., Ltd.191
已完成
1 期
A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy ParticipantsHealthy SubjectsNCT05483998OrsoBio, Inc100